13F-HR filed by TCG Crossover Management, LLC
TCG Crossover Management, LLC filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-14, with 36 holding rows worth $1,180,307,005.
- Accession
- 0001214659-24-019064
- Filer
- CIK 1839948
- Filed
- 2024-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2024
A holdings report, 36 entries on the cover page, a total value of $1,180,307,005 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,180,307,005 with VALUE read as dollars as filed, 13F file number 028-22283. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 3,670,206 | $138,476,872 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 2,650,150 | $95,193,388 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 6,964,375 | $75,215,250 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 6,056,596 | $69,771,986 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 2,112,984 | $56,395,543 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 3,033,560 | $55,150,121 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 12,362,205 | $52,415,749 | dollars as filed | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 879,344 | $51,063,506 | dollars as filed | |
| XENCOR INC | 98401F105 | COMMON STOCK | 2,427,138 | $48,809,745 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 1,989,103 | $46,763,812 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 1,063,000 | $46,655,070 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 5,319,148 | $46,276,588 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 2,890,816 | $46,224,148 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 1,477,593 | $37,988,916 | dollars as filed | |
| THIRD HARMONIC BIO INC | 88427A107 | COM | 2,415,000 | $32,723,250 | dollars as filed | |
| ASTRIA THERAPEUTICS INC COM | 04635X102 | Stock | 2,761,861 | $30,408,090 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 2,470,265 | $29,914,909 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 1,423,642 | $27,817,965 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 550,000 | $27,769,500 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 3,858,000 | $24,305,400 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 486,957 | $23,929,067 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 5,250,000 | $18,742,500 | dollars as filed | |
| MBX BIOSCIENCES INC COM | 55287L101 | Stock | 650,000 | $16,887,000 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 4,643,812 | $15,045,951 | dollars as filed | |
| ADVERUM BIOTECHNOLOGIES INC | 00773U207 | COM NEW | 2,008,339 | $14,098,540 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 584,955 | $9,347,581 | dollars as filed | |
| VISTAGEN THERAPEUTICS INC | 92840H400 | COM | 2,676,580 | $8,056,505 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 231,820 | $7,624,560 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 922,335 | $7,369,457 | dollars as filed | |
| NEKTAR THERAPEUTICS | 640268108 | COM | 4,000,000 | $5,200,000 | dollars as filed | |
| AEROVATE THERAPEUTICS INC | 008064107 | COM | 2,240,809 | $4,683,291 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 483,000 | $4,588,500 | dollars as filed | |
| KODIAK SCIENCES INC | 50015M109 | COM | 1,008,158 | $2,631,292 | dollars as filed | |
| AN2 THERAPEUTICS INC | 037326105 | COM | 1,555,118 | $1,663,976 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 316,195 | $689,305 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 86,795 | $409,672 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-24-019064 | this filing | 2024-11-14 | acceptance time not in the bulk data set |